



# **B11 – How should antimicrobial properties of an orthopaedic titanium implant be evaluated in animal and clinical studies?**

Assoc. Prof. Margarita Trobos

Department of Biomaterials, Institute of Clinical Sciences, Sahlgrenska Academy,  
University of Gothenburg, Sweden





3rd Meeting of the International Consensus Meeting  
8-10 of May, 2025 Istanbul



**Alexander W Burns**  
Australia



**Humberto González-Ugalde**  
Mexico



**Noreen J Hickok**  
USA



**Liliana A Morales-Laverde**  
Sweden



**Ebru Oral**  
USA



**Claudia Siverino**  
Switzerland



**2747**

Number of articles retrieved

**287**

Full text review/Screening


**51**

Final number of publications

- Systematic review of studies **from 2015 to 2024**, focusing on **animal (n=42)** and **human (n=9) studies** involving **antimicrobial titanium implants**



## Antimicrobial Strategies for Orthopaedic Ti implants



### Background & Aim:

- **Implant-associated infections** are a major complication in orthopaedic surgery
- Novel titanium **implants with antimicrobial properties** are being developed
- **Lack of standardization** in evaluating their efficacy *in vivo*
- **Aim:** Identify **key criteria** to evaluate such implants, focusing on animal and clinical studies
- Most studies reported **reduced infection rates and improved clinical outcomes** with antimicrobial coatings






# 3rd Meeting of the International Consensus Meeting 8-10 of May, 2025 Istanbul



## Outcome evaluation and analytical techniques:

### 1. Bacterial Viability

- Live/dead staining



### 2. Bacterial Adhesion

- CFU counting after detachment
- SEM imaging



### 3. Reduction in Biofilm Formation

- Crystal violet staining (biofilm biomass)
- CLSM & SEM imaging
- CFU counting from dispersed biofilm




### 4. Antibiotic Resistance

- MIC testing
- Whole-genome sequencing




### 5. Infection Rates

- Microbiological cultures
- Imaging (X-ray,  $\mu$ -CT, MRI, IVIS bioluminescence)




### 6. Inflammatory Response

- Blood tests
- Histological analysis



### 7. Clinical Outcomes

- Recovery & complication rates
- Clinical exams, imaging



### 8. Functional Outcomes

- Mobility tests
- Pain scales
- Functional scoring systems



# 3rd Meeting of the International Consensus Meeting 8-10 of May, 2025 Istanbul



## Models:




**Mice** (C57BL/6) (n=5-10)




**Rats** (Sprague-Dawley) (n=5-10)



**Rabbits** (New Zealand White) (n=6)



**Sheep** (n=7)



**Minipigs** (n=7)

## Implants:



screws




rods



nails/pins



plates



femur



tibia



## In animal studies, key factors include:

- **Choice of model** — rodents, rabbits, or large animals with relevance to human bone healing
- **Bacterial inoculation** — clinically relevant species (*S. aureus*, *S. epidermidis*) with standardized doses ( $10^6$  to  $10^8$  CFU) to avoid sepsis or rapid clearance
- **Infection** — acute or chronic infections should reflect the intended clinical scenario
- **Timing** — pre- or post-implantation infection; use of planktonic bacteria or pre-formed biofilm on implant depending on the model
- **Follow-up** — ranges from 1 week to several months
- **Evaluation** — assess bacterial viability, biofilm formation, inflammatory response, infection rates, clinical outcomes
- **Design** — include blinding, controls, power analysis, and ethical compliance



# 3rd Meeting of the International Consensus Meeting 8-10 of May, 2025 Istanbul



## In clinical studies, key factors include:

- **Design** — use prospective RCTs or observational studies
- **Patient population** — high-risk orthopaedic patients (arthroplasty or trauma; n=5–653)
- **Implant types** — prostheses, nails, fixation materials
- **Antimicrobial coatings** — gentamicin, vancomycin, iodine, silver
- **Infection sites** — bone and joint
- **Outcomes** — clinical (recovery & infection rates); functional (mobility & pain)
- **Follow-up** — long-term (months to years; 1 year common)
- **Design** — apply standardised definitions, ensure ethical compliance



## **Question:**

**❖ How should antimicrobial properties of an orthopaedic titanium implant be evaluated in animal and clinical studies?**





## ❖ Response:

- The antimicrobial properties of orthopaedic titanium implants should be **evaluated using a combination of *in vitro*, animal, and clinical studies** to ensure comprehensive assessment of safety and efficacy.
- **Animal models** provide crucial insights into the **biological interactions** of implants with host tissues and pathogens, while **human studies** validate **clinical applicability**.
- To effectively evaluate the antimicrobial properties of new orthopaedic titanium implants, it is recommended to use a combination of **well-established animal models, appropriate bacterial species**, standardized inoculation **doses**, and **comprehensive and quantitative** analytical techniques.

**Level of Evidence: Moderate**



❖ **Vote:**

**Agree**      **n=42; 98%**

**Disagree**      **0**

**Abstain**      **n=1; 2%**